#United States #Lake Forest #Sonorous NV #Paul Brooke #Joel Harris

Leadership Transition at Sonorous NV, Inc.

Sonorous NV, Inc., a key player in the medical device industry, announced a significant leadership transition that is set to steer the company into a new chapter of innovation and growth. On March 27, 2026, the company disclosed that Paul Brooke, a well-respected member of the Board, has taken on the role of Chairman. In a significant shift, Joel Harris has been promoted from President to Chief Executive Officer, succeeding David Ferrera, who has stepped down to focus on other endeavors.

A Vision for the Future

In light of these changes, Joel Harris expressed his enthusiasm about his new position, emphasizing the importance of this moment for the company. “I am honored to lead Sonorous at this important time. We remain focused on advancing the BosSTENT™ and transforming outcomes for patients,” Harris stated. With over 35 years of experience in the medical device industry, Harris brings to the table a wealth of expertise in sales, marketing, clinical development, and executive leadership that is crucial for driving Sonorous forward.

Paul Brooke, now serving as Chairman, brings extensive governance and strategic oversight experience to his new role. He reflected on the company’s promising future, saying, “Sonorous is entering an exciting phase of clinical and regulatory progress. With Joel Harris as CEO and our executive team, we are confident the team will deliver meaningful innovation to patients without distraction.”

Notable Achievements

Sonorous NV is currently on a strong growth trajectory, primarily due to its flagship product, the BosSTENT™. This cutting-edge device is the first braided, self-expanding cerebral venous stent specifically designed to address issues related to venous sinuses. The company has made impressive strides in recent months as it continues to expand its capabilities and market reach. Notable achievements include:

• - Pioneering the BosSTENT™: The first of its kind in the market, addressing the needs of patients with cerebral venous conditions.
• - Received Key Authorizations: The French ANSM and CPP have approved a pivotal European study to support future CE Mark submissions, while Health Canada has granted ITA approval for including Canadian sites in the upcoming study.
• - FDA Breakthrough Device Designation: The BosSTENT™ has been recognized for its potential in treating pulse-synchronous tinnitus due to venous sinus stenosis, granting it prioritized review and possible NTAP eligibility.

These accomplishments signal that Sonorous is not only committed to advancing its current offerings but is also preparing for IDE submissions and broader market approvals.

Commitment to Patients

With its focus firmly on developing minimally invasive solutions, Sonorous Neurovascular aims to improve the quality of life for patients suffering from pulsatile tinnitus and other cerebral venous conditions. “We are dedicated to innovation that truly transforms the healthcare landscape,” Harris added, reinforcing the company’s commitment to patient-centric solutions.

About Sonorous Neurovascular

Sonorous Neurovascular is a trailblazer in the medical device arena, concentrating on innovative technologies inspired by physicians for the treatment of cerebral venous diseases. The company’s flagship device, the BosSTENT™, is revolutionizing treatment for symptomatic venous sinus stenosis and exemplifies its commitment to superior performance and innovative solutions.

For further inquiries, please contact:
James D. Nonato, Vice President
Sonorous NV, Inc.
Email: [email protected]
Phone: +1 (888) 830 1445

Together, under the new leadership of Joel Harris and Paul Brooke, Sonorous NV is poised for groundbreaking advancements that will significantly enhance patient care in the coming years.